Related Experiment Videos
Amlodipine: a pharmacoeconomic review
Simona de Portu1, Lorenzo G Mantovani
1CIRFF-Center of Pharmacoeconomics, Federico II University of Naples, Naples, Italy. sdeportu@unina.it
Journal of Medical Economics
|May 20, 2009
Summary
Amlodipine use in coronary artery disease (CAD) patients is cost-effective and may save costs. This calcium channel blocker offers superior protection against stroke and myocardial infarction compared to other treatments.
Area of Science:
- Cardiovascular Medicine
- Pharmacoeconomics
- Clinical Trials
Background:
- Coronary artery disease (CAD) management involves evaluating treatment efficacy and economic impact.
- Calcium channel blockers, such as amlodipine, are frequently used in cardiovascular care.
Purpose of the Study:
- To assess the pharmacoeconomic impact of amlodipine in patients with coronary artery disease (CAD).
Main Methods:
- A review of clinical trials comparing amlodipine with other treatments was conducted.
- Pharmacoeconomic studies quantifying the economic impact of amlodipine were identified.
Main Results:
- Amlodipine demonstrated greater protection against stroke and myocardial infarction compared to angiotensin receptor blockers (ARBs).
- Compared to ACE inhibitors and older drug classes, amlodipine also showed improved stroke prevention.
- Pharmacoeconomic analyses indicated fewer hospitalizations and invasive procedures with amlodipine use, at a modest incremental cost.
- Improved clinical outcomes and cost savings were associated with amlodipine.
Conclusions:
- Amlodipine is cost-effective and predicted to be cost-saving for CAD patients compared to usual care.
- Amlodipine warrants consideration as a preferred agent for managing CAD.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
01:21Pharmacodynamics: Overview and Principles
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...